Current
16.1×
5-Year Average
19.2×
All-Time High
240.3×
All-Time Low
4.0×
P/E Ratio daily chart for Bristol-Myers Squibb (BMY)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
P/E ratio is not shown for periods when TTM earnings were negative.
Historical P/E Ratio for Bristol-Myers Squibb (BMY) from 2001 to 2025
| 2025 | $110.09B | $7.05B | 15.6× | — | |
| 2024 | $114.76B | −$8.95B | — | — | |
| 2023 | $104.01B | $8.03B | 13.0× | -11.0× | |
| 2022 | $151.67B | $6.33B | 24.0× | +4.8× | |
| 2021 | $134.24B | $6.99B | 19.2× | — | |
| 2020 | $139.69B | −$9.02B | — | — | |
| 2019 | $122.90B | $3.44B | 35.7× | +18.5× | |
| 2018 | $84.83B | $4.92B | 17.2× | -82.3× | |
| 2017 | $100.25B | $1.01B | 99.6× | +77.6× | |
| 2016 | $97.71B | $4.46B | 21.9× | -50.6× | |
| 2015 | $113.44B | $1.56B | 72.5× | +23.6× | |
| 2014 | $97.99B | $2.00B | 48.9× | +14.7× | |
| 2013 | $87.59B | $2.56B | 34.2× | +6.8× | |
| 2012 | $53.58B | $1.96B | 27.3× | +11.3× | |
| 2011 | $59.59B | $3.71B | 16.1× | +1.5× | |
| 2010 | $45.20B | $3.10B | 14.6× | +9.9× | |
| 2009 | $49.46B | $10.61B | 4.7× | -4.1× | |
| 2008 | $46.03B | $5.25B | 8.8× | -15.4× | |
| 2007 | $52.40B | $2.17B | 24.2× | -8.4× | |
| 2006 | $51.67B | $1.58B | 32.6× | +17.6× | |
| 2005 | $44.93B | $3.00B | 15.0× | -5.9× | |
| 2004 | $49.83B | $2.39B | 20.9× | +3.3× | |
| 2003 | $55.48B | $3.15B | 17.6× | -6.8× | |
| 2002 | $50.49B | $2.07B | 24.4× | +5.4× | |
| 2001 | $98.79B | $5.19B | 19.0× | — |
- 202515.6×
- 2024—
- 202313.0×
- 202224.0×
- 202119.2×
- 2020—
- 201935.7×
- 201817.2×
- 201799.6×
- 201621.9×
- 201572.5×
- 201448.9×
- 201334.2×
- 201227.3×
- 201116.1×
- 201014.6×
- 20094.7×
- 20088.8×
- 200724.2×
- 200632.6×
- 200515.0×
- 200420.9×
- 200317.6×
- 200224.4×
- 200119.0×
About P/E Ratio at Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb (BMY) P/E ratio is 16.1× as of June 5, 2026. The 5-year average is 19.2×. The sector median currently stands at 25.0×. The current ratio is at the 24th percentile of its own 10-year history.
Bristol-Myers Squibb (BMY) historical P/E ratio has ranged from a low of 4.0× (2010) to a high of 240.3× (2018) in the available daily series.
The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.
Bristol-Myers Squibb P/E Ratio by Year
Bristol-Myers Squibb P/E Ratio 2025: 15.6×
Bristol-Myers Squibb (BMY) P/E ratio in 2025 was 15.6×, expanded from 13.0× the prior year.
Bristol-Myers Squibb P/E Ratio 2023: 13.0×
Bristol-Myers Squibb (BMY) P/E ratio in 2023 was 13.0×, contracted from 24.0× the prior year.
Bristol-Myers Squibb P/E Ratio 2022: 24.0×
Bristol-Myers Squibb (BMY) P/E ratio in 2022 was 24.0×, expanded from 19.2× the prior year.
Bristol-Myers Squibb P/E Ratio 2021: 19.2×
Bristol-Myers Squibb (BMY) P/E ratio in 2021 was 19.2×, contracted from 35.7× the prior year.
Bristol-Myers Squibb P/E Ratio 2019: 35.7×
Bristol-Myers Squibb (BMY) P/E ratio in 2019 was 35.7×.
Sector peers by P/E Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/E Ratio — table
Healthcare peers of Bristol-Myers Squibb (BMY), ranked by P/E ratio.
| 23.1× | |
| 22.2× | |
| 22.2× | |
| 21.7× | |
| 21.6× | |
| 21.6× | |
| 21.1× | |
| 21.1× | |
| 21.0× | |
| 20.9× | |
| 20.7× | |
| 20.4× | |
| 19.7× | |
| 18.9× | |
| 18.8× | |
| 18.5× | |
| 18.2× | |
| 15.8× | |
| 13.3× | |
| 13.1× | |
| 12.3× | |
| 11.1× | |
| 8.6× | |
| 7.9× | |
| 7.2× |
- 22.2×
- 22.2×
- 21.7×
- 21.6×
- 21.6×
- 21.1×
- 21.0×
- 20.9×
- 20.7×
- 19.7×
- 18.9×
- 18.5×
- 15.8×
- 13.3×
- 13.1×
- 11.1×
- 7.9×
Frequently asked questions
Bristol-Myers Squibb (BMY) Key Financials
Charts, filings, and peer comparison for every metric